Abiraterone
- Generic Name
- Abiraterone
- Brand Names
- Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO
- CAS Number
- 154229-19-3
- Unique Ingredient Identifier
- G819A456D0
- Background
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...
- Indication
Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Associated Therapies
- -
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- Conditions
- Interventions
- Drug: AbirateroneDrug: BicalutamideDrug: DegarelixDrug: FlutamideDrug: DocetaxelDrug: Goserelin AcetateDrug: Histrelin AcetateDrug: Leuprolide AcetateDrug: NilutamideProcedure: OrchiectomyOther: Quality-of-Life AssessmentRadiation: Radiation TherapyDrug: PrednisoneProcedure: Radical ProstatectomyDrug: Triptorelin
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1273
- Registration Number
- NCT03678025
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Parkland Memorial Hospital, Dallas, Texas, United States
🇺🇸UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 10
- Registration Number
- NCT03649841
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study to Evaluate CCS1477 in Advanced Tumours
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- CellCentric Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT03568656
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States
Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 32
- Registration Number
- NCT03565835
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Androgen Reduction in Congenital Adrenal Hyperplasia
- Conditions
- Interventions
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Registration Number
- NCT03548246
- Locations
- 🇺🇸
Children's Medical Center, Dallas, Texas, United States
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸National Institutes of Health, Bethesda, Maryland, United States
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2024-11-28
- Target Recruit Count
- 17
- Registration Number
- NCT03511196
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Phase II Randomized Trial of Radiation Therapy in Oligometastatic mCRPC Prostate Cancer (ARTO)
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Lorenzo Livi
- Target Recruit Count
- 174
- Registration Number
- NCT03449719
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 102
- Registration Number
- NCT03436654
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Northwestern University, Evanston, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 11
- Registration Number
- NCT03418324
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
- Conditions
- Interventions
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 223
- Registration Number
- NCT03419234
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, United States
🇺🇸Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.